Lipoatrophy, Lipodystrophy, and Insulin Resistance
- 15 August 2000
- journal article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 133 (4) , 304-306
- https://doi.org/10.7326/0003-4819-133-4-200008150-00017
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy SyndromesAnnals of Internal Medicine, 2000
- The perils of portliness: causes and consequences of visceral adiposity.Diabetes, 2000
- Surgical implantation of adipose tissue reverses diabetes in lipoatrophic miceJournal of Clinical Investigation, 2000
- Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.Diabetes Care, 1999
- Effect of troglitazone on body fat distribution in type 2 diabetic patients.Diabetes Care, 1999
- Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.Diabetes Care, 1999
- Surgical removal of visceral fat reverses hepatic insulin resistance.Diabetes, 1999
- Life without white fat: a transgenic mouseGenes & Development, 1998
- Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophyGenes & Development, 1998
- Troglitazone action is independent of adipose tissue.Journal of Clinical Investigation, 1997